Centessa Pharmaceuticals plc (NASDAQ: CNTA) - quick inside look
What's happening inside
* Management has pivoted capital and focus toward its OX2R (orexin receptor 2) agonist franchise (ORX750, ORX142, ORX489) after discontinuing several prior programs (SerpinPC and LB101).
* The company out‑lice...